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Abstract
Uric acid (UA) is a metabolite of purine degradation and is involved in gout flairs and kidney stones formation. GLUT9
(SLC2A9) was previously shown to be a urate transporter in vitro. In vivo, humans carrying GLUT9 loss-of-function mutations
have familial renal hypouricemia type 2, a condition characterized by hypouricemia, UA renal wasting associated with kidney
stones, and an increased propensity to acute renal failure during strenuous exercise. Mice carrying a deletion of GLUT9 in the
whole body are hyperuricemic and display a severe nephropathy due to intratubular uric acid precipitation. However, the precise
role of GLUT9 in the kidney remains poorly characterized. We developed a mouse model in which GLUT9 was deleted
specifically along the whole nephron in a tetracycline-inducible manner (subsequently called kidney-inducible KO or kiKO).
The urate/creatinine ratio was increased as early as 4 days after induction of the KO and no GLUT9 protein was visible on kidney
extracts. kiKO mice are morphologically identical to their wild-type littermates and had no spontaneous kidney stones. Twenty-
four-hour urine collection revealed a major increase of urate urinary excretion rate and of the fractional excretion of urate, with no
difference in urate concentration in the plasma. Polyuria was observed, but kiKO mice were still able to concentrate urine after
water restriction. KiKO mice displayed lower blood pressure accompanied by an increased heart rate. Overall, these results
indicate that GLUT9 is a crucial player in renal handling of urate in vivo and a putative target for uricosuric drugs.
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Introduction
In humans, by contrast to most mammals, uric acid is the end
product of purine metabolism, due to silencing mutations
acquired over time in the gene coding for uricase, the hepatic
enzyme responsible for uric acid degradation into allantoin
[41]. Inactivating uricase increases serum uric acid (SUA)
levels 5–8-folds and several undemonstrated hypotheses have
been proposed to explain why evolution has favored high
SUA levels in humans. However, if high SUA brings possible
advantages, such as neuro- or immuno-protection [2, 22, 25],
it is also increasing the risk for gout and/or kidney stone for-
mation [14, 28]. Indeed, significant amount of uric acid is
present in urine and is poorly soluble in this mainly acidic
milieu. During the past decades, the prevalence of gout and
kidney stones has increased and represents a significant bur-
den for the health system [13, 21, 36].
Urate balance depends on its rate of production and degra-
dation in the liver and on its excretion, mainly by the kidneys.
Previous physiological work and genome wide association
study analysis have identified several transporters instrumen-
tal in transporting urate in both direction (reabsorption and
secretion) in the proximal tubule of the kidneys and in keeping
serum uric acid concentration constant [8, 12, 19, 20, 23, 40].
One of them, GLUT9, encoded by SLC2A9, is responsible for
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1.7 to 5.3% of the variation of SUA in humans [19, 40].
GLUT9, originally cloned by homology to the glucose trans-
porter family [11], has been identified as a urate transporter [5,
6]. Its role in urate homeostasis has been validated by the
finding of loss-of-function mutations resulting in type 2 famil-
ial renal hypouricemia [3, 9, 10, 26, 40]. This inherited disease
(OMIM # 612076) is characterized by low levels of SUA
mainly due to decreased renal tubular UA reabsorption and
high uric acid fractional excretion and is predisposing to
exercise-induced acute renal failure and kidney stone
formation.
Even if mice have specific ways of handling uric acid (pres-
ence of a functional uricase in the liver; different organization
of uric acid transporters along the renal tubule), they share
several characteristics regarding uric acid metabolism and
transport with humans and offer suitable models to study uric
acid transport.
GLUT9 is mainly expressed in the liver and the kidneys [4,
17, 29]. In the latter organ, GLUT9 is expressed in the prox-
imal tubule in humans and mice and in the distal tubule of the
mouse kidney [31]. Others and our previous work have shown
that constitutive deletion of GLUT9 in the whole mice leads to
hyperuricemia, hyperuricosuria, and early-onset severe ne-
phropathy [31]. Further, specific deletion of GLUT9 in the
liver alone led to hyperuricemia, suggesting a role for
GLUT9 in transporting UA into the hepatocytes and making
it available for degradation by uricase [31]. Recently, the role
of GLUT9 in the intestine has been unraveled by the knock-
out of this transporter in enterocytes [7].
However, the role of GLUT9 in the kidney still remains
elusive.We have thus generated a kidney-inducible knock-out
mouse model for GLUT9. This allowed us to reveal an impor-
tant role for renal GLUT9 in uric acid homeostasis.
Materials and methods
Materials
Products were purchase from Sigma-Aldrich (St. Louis, MO)
unless otherwise stated.
Animals
All animal studies were approved by the state veterinarian
Office (Office vétérinaire cantonal, Canton de Vaud,
Switzerland). All breeding and cohort colonies were hosted
in our animal facility under approved protocols. Mice were
housed four to five per cage, with free access to water and
food, in a temperature and humidity-controlled room with an
automatic 12/12-h light/dark cycle. Animals were fed a stan-
dard mouse diet (#3800) from KLIBA (Kaiseraugst,
Switzerland).
Generation of inducible kidney-specific knock-out
animals
In order to obtain an inducible cre recombination specifically
in the tubular cells of the kidney, a tetracycline-ON system
was used. Mice with floxed Glut9 allele [31] were bred with
Pax8-rtTA/LC-1 cre-transgenic mice in a C57BL6/N back-
ground [38]. Females and males of 6–8-week triple-
transgenic mice and their littermate controls (either with
Pax8-rtTA or LC-1 cre transgene alone) were treated with
2mg/ml doxycycline in 2% sucrose drinkingwater for 14 days
in order to induce recombination. Fresh spot urine samples
were obtained during doxycycline induction and analysis of
urate-over-creatinine ratio was performed. Recombination
was assessed by PCR using the following primer for Glut9a:
mGlut9aF (GGAGCTTGCTTTAGCTTCCC) and mGlut9aR
(TGG ACC AAG GCA GGG ACA A), and for Glut9b:
mGlut9bF (AAC TCC GCA GAA ACC AAG GAA AGC)
and mGlut9bR (ACCCATGATGAACCGTCCCA). PCR-
generated fragments were 664 and 613 bp for Glut9a WT
and kiKO respectively and 481 and 430 bp for Glut9b WT
and kiKO respectively. Unless otherwise specified, mice were
used 4 months after the end of doxycycline induction.
Genotyping
Genotypes were determined by PCR on total genomic DNA
extracted from ear biopsy by NaOH digestion and using the
following primers: Glut9F (CTG TCC AGATGT TGT CTA
GG), Glut9R (GTTATG ATG CAG GAG CTTAGC), LC1-
Cre-F (TCG CTG CAT TAC CGG TCG ATG C), LC1-Cre-R
(CCATGA GTG AAC GAA CCT GGT CG), Pax8-F (CCA
TGT CTA GAC TGGACAAGA), Pax8-R (CTC CAGGCC
ACA TAT GAT TAG). PCR reactions were carried out on a
PeqStar 2x Thermal Cycler (PeqLab Biotechnologie,
Erlangen, Germany) using GoTaq DNA Polymerase
(Promega Corporation, Madison, WI). PCR protocol was
5 min at 95 °C followed by 35 cycles (1 min at 95 °C, 1 min
at 60 °C, and 2 min at 72 °C) and by 10 min at 72 °C. This
generated a fragment of 361 bp for GLUT9 wild-type allele
and of 460 bp for the floxed allele. Pax8-rtTA and LC1-cre
transgene were detected by fragments of 650 and 430 bp
respectively.
Metabolic cages, blood, and urinary analysis
The mice were placed in individual metabolic cage
(Tecniplast, Buguggiate, Italy) for 2 days in order to get used
to the new environment, before two cycles of 24-h urine col-
lection. Food and water intake were measured, and the 24-h
collected feces were weighed. Determination of excretion rate
was calculated as the concentration of a given substance in the
volume of the 24-h urine. Body weight was also determined.
1740 Pflugers Arch - Eur J Physiol (2018) 470:1739–1751
Plasma and urine chemistry were analyzed using a Roche/
Hitachi 902 robot system (Roche, Mannheim, Germany).
Osmolality was measured with a vapor pressure osmometer
(Vapro 5520, Wescor, South Logan, USA).
Microdissection of nephron segments
After deep anesthesia by intraperitoneal injection by
Ketanarkon (Streuli, Pharma AG, Switzerland; 100 μg/g body
weight) and Rompun (Bayer, Leverkusen, Germany; 10 μg/g
body weight), the left kidney was perfused with DMEM/F12
(1:1, Life Technologies, Carlsbad, USA) supplemented with
40mg/ml of Liberase Blendzyme 2 (Roche, Switzerland). The
kidney was cut in thin pyramids along the corticomedullary
axis and incubated 40 min at 37 °C. After washes with
DMEM/F12 to stop the digestion, microdissection of glomer-
ulus (glom), proximal convoluted tubule (PCT), proximal
straight tubule (PST), medullary thick ascending limb
(TAL), distal convoluted tubule and cortical connecting tubule
(DCT-CNT), or cortical collecting duct (CCD) was performed
in DMEM/F12 (1:1). Tubular length was measured with an
ocular micrometer, and pools of 10–20microdissected tubules
covering a total tubular length of ∼ 10 mm/pool were trans-
ferred in sample buffer for Western blot analysis.
Osmolality measurements in kidney fragments
Under deep anesthesia and after cervical dislocation, kidneys
were removed and cut in slices and small parts of cortex and
medulla were dissected and weighted. Fifty microliters of wa-
ter was added to the samples. After centrifugation 10 min at
12,000 rpm, the supernatants were collected and osmolality of
the sample was measured and normalized to the weight of the
fragment.
Immunoblotting
For protein extraction, half kidneys were homogenized in
RIPA buffer (Tris pH 7.2 50 mM, NaCl 150 mM, NP40 1%,
SDS 0.1%, Na-deoxycholate 0.5% with proteases inhibitor)
using TissueLyser (Qiagen, Hilden, Germany). After centrifu-
gation at 12,000 rpm for 15 min, the supernatants were col-
lected and total protein concentration was determined using a
BCA protein assay kit (Pierce, Rockford, IL). Equal amounts
of protein were separated on 10% SDS polyacrylamide gels
and blotted onto nitrocellulose membrane (Whatman, Dassel,
Germany). Primary antibodies used were GLUT9 (1:500,
[31]), AQP2 (1:500, kindly provided by Prof. J. Loffing,
Institute of Anatomy, University of Zurich), NCX1 (1:1000,
[30]), and actin (1:500, Sigma, St-Louis, USA). Secondary
anti-rabbit and anti-mouse antibody (1:10,000, Amersham
Biosciences, Buckinghamshire, UK) were detected by
chemiluminescence (Super Signal West Pico, Thermo
Scientific, Rockford, USA).
Real-time PCR
Half kidneys were sampled and homogenized in a TRI
Reagent solution (Ambion, Austin, USA) followed by an ex-
traction with 1-bromo-3-chloropropane reagent (BCP,
Molecular Research Center, Cincinnati, USA) and an
isopropanol precipitation. RNA (1μg) was reverse transcribed
using a PrimeScript RT reagent kit (Takara Biotechnology,
Otsu, Japan) according to manufacturer’s guidelines.
TaqMan Gene Expression Assays (Applied Biosystems,
USA) were used to detect Urat1 (Mm01236822_m1), Mrp4
(Mm01226381_m1), Abcg2 (Mm00496364_m1), Npt1
(Mm00436577_m1), Npt4 (Mm00506321_m1), Oat1
(Mm00456258_m1), Oat3 (Mm00459534_m1), Oat10
(Mm00506015_g1), uricase (Uox, Mm00447661_m1), xan-
thine dehydrogenase (Xdh, Mmoo442110_m1), V2r
(Mm01193534_g1), Aqp2 (Mm00437575_m1), Glut9a
(Mm01211146_m1), Glut9b (Mm00455117_m1), and Actb
(actin, beta, VIC/MGB Probe, Primer Limited).
For quantification of the recombination of Glut9, primers
targeting exon 4 which is deleted after cre recombination were
designed (Glut9 ex4 F: TTG GGA GGA AGT CCA CAT
TGC TGG, Glut9 ex4 R: TCC ATC CAC ACC CAT GAT
GAA CCG) and used with primers for Actb: Actb F (GTC
CAC CTT CCA GCA GAT GT) and Actb R (AGT CCG
CCT AGA AGC ACT TGC). Quantitative real-time PCRs
were carried out on an ABI PRISM 7500 equipment
(Applied Biosystems, Carlsbad, USA) in triplicate for each
sample, either with TaqMan Universal PCR Master Mix
(Applied Biosystems) or SYB green PCR Master Mix
(Applied Biosystems) in a final volume of 20 μl.
The relative expression of each gene was calculated using
the comparative 2[−ΔΔCT] method [42], normalized to Actb.
Data are represented as relative fold-change compared to con-
trol mice.
Fixation, tissue processing, and immunofluorescence
Mice were anesthetized by intraperitoneal injection of
Ketanarkon (Streuli, Pharma AG, Switzerland; 100 μg/g
of body weight) and Rompun (Bayer, Leverkusen,
Germany; 10 μg/g of body weight).The left kidney was
perfused via the abdominal aorta with paraformaldehyde
4% in PBS (137-mM NaCl, 2.7-mM KCl, 0.9-mM
KH2PO4, 6.4-mM NaH2PO4, pH 7.4). Kidneys were in-
cubated in 30% sucrose in PBS for at least 24 h before
being embedded in Tissue-Tek OCT compound (Sakura
Finetek, Netherland) and frozen. Eight-micrometer thick
cryosections were incubated 1 h with blocking buffer
(NP-40 0.5%, BSA 2%, normal goat serum (NGS) 3%
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in PBS) at room temperature. Incubation with primary
antibodies diluted in blocking buffer without NGS was
performed overnight at 4 °C. Used primary antibodies
were GLUT9 (1:500, [31]), NCX1 (1:1000, [30]), and
AQP2 (1:500, kindly provided by Prof. J. Loffing,
Institute of Anatomy, University of Zurich). After wash-
ing three times with PBS, sections were incubated 1 h at
r oom t empe r a t u r e w i t h s e conda ry an t i b od i e s
AlexaFluor488 (1:2000 diluted in blocking buffer without
BSA, Invitrogen, Carlsbad, USA) and then washed four
times with PBS. The sections were then mounted using
Fluoromount-G mounting medium (Southern Biotech,
Birmingham, USA). Fluorescent images were visualized
using a laser scanning confocal microscope (Leica SP5
AOBS Confocal Microscope).
Telemetry
Measurements of blood pressure were performed by telemetry
using a specific transducer for mice (Data Sciences
International, St. Paul, USA). Under deep anesthesia, catheter
was introduced into the left carotid and the transducer was
placed in the abdominal cavity. Mice were placed in the re-
cording cages individually, but were keeping olfactory and
visual contact with conspecifics and were able to run freely.
At least 14 days after surgery, the device was switched on and
the mouse cage was placed on an antenna. The signal was then
processed by a software and translated into pressure curve
(Dataquest A.R.T.™ acquisition and analysis system (Data
Sciences International, St. Paul, USA)).
Statistical analyses
Results are presented as means ± SD. Statistical analyses were
performed using GraphPad Prism 6.0 software (GraphPad
Software Inc.). Comparison between groups was performed
using one-way ANOVA test followed by Bonferoni post hoc
test. Student’s t test (2-tailed) for unpaired data was used. p
values < 0.05 were considered as statistically significant.
Results
GLUT9 localization in the mouse kidney
GLUT9 precise localization in the kidney is subject to contro-
versy as several reports have shown various tubular expres-
sion and membrane sorting. Indeed, in transfected MDCK
cells, murine GLUT9 was observed at the basolateral mem-
brane [17], whereas immunohistochemical staining of
GLUT9 on mouse kidney sections showed both apical and
basolateral staining [31].
We took advantage of a newly in-house produced anti-
GLUT9 antibody to analyze GLUT9 expression in vivo
(Supplementary Fig. S1). First, we microdissected different
parts of the nephron (glomerulus, PCT, PST, TAL, DCT, and
CCD) of wild-typemice and looked for GLUT9 expression. A
strong signal appearing at molecular weight 55 kDa was read-
ily visible in the distal convoluted tubule (DCT), and only
after longer exposure in the proximal convoluted tubule
(PCT) as well (Fig. 1a). Immunostaining of GLUT9 revealed
staining in the cortical kidney (Fig. 1b). More specifically, we
found strong basolateral GLUT9 staining in the DCT (Fig.
1c), as indicated by perfect co-localization of GLUT9 with
NCX1, the basolateral calcium-sodium exchanger type 1
expressed in this segment [24]. Moreover, no co-localization
could be detected with AQP2 (Fig. 1c), an apical water chan-
nel expressed in the same cells. No staining for GLUT9 in
proximal tubules was visible on kidney sections, probably
due to the weak GLUT9 expression, as anticipated from the
Western blot (Fig. 1a). This data shows strong evidence for
basolateral expression of GLTU9 in the mouse DCT and
weaker expression in the proximal tubule.
Doxycycline-inducible GLUT9 deletion in the kidney:
molecular analysis
In order to determine the specific role of GLUT9 in the
kidney, an inducible kidney-specific Glut9 knock-out
mouse model (hereafter called kiKO) was generated by
using mice carrying, on the one hand, the floxed GLUT9
allele [31] and, on the other hand, the Pax8-rtTA/LC-1 cre
recombinase [38]. Glut9flox/flox/Pax8-rtTA/LC1 (kiKO)
mice and littermate controls (Glut9flox/flox/Pax8-rtTA or
Glut9flox/flox/LC1, called controls hereafter) were treated
with doxycycline added to drinking water for 14 days.
Recombination of Glut9a and Glut9b isoforms was ob-
served at least 6 days after doxycycline treatment (Fig.
S2). Four months after the end of the doxycycline treatment,
mice still exhibited recombination of Glut9 in the kidney
(Fig. 2a) with only 7.4 ± 2.7% of residual Glut9 RNA ex-
pression (Fig. 2b). Renal GLUT9 protein expression level
confirmed the absence of GLUT9 protein in the whole kid-
ney extract of kiKO mice compared to controls (Fig. 2c). In
the liver, Traykova-Brauch et al. [38] have shown a partial
Pax8-rtTA-mediated recombination in some periportal he-
patocytes. We checked whether Glut9 recombination also
occurred in the liver of kiKO mice. During doxycycline
induction, a partial recombination of Glut9 could be ob-
served in the liver of the mice (Fig. S3a). This recombina-
tion was still observed 4 months after induction, with de-
creased liver GLUT9 expression of 68.4 ± 15.6% and 61.6
± 29.3% for respectively mRNA and protein (Fig. S3b, c).
Of note, females were less affected by the recombination in
the liver than males. As additional control for organ specific
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deletion, we also looked at putative GLUT9 deletion along
the intestine. Fig. S4a, b indicates an absence of Glut9 re-
combination in the ileum and in the colon.
Doxycycline-inducible Glut9 deletion in the kidney:
functional analysis
The time-course of the effect of doxycycline-mediated
Glut9 deletion in the kidney was monitored by measure-
ment of the urate-over-creatinine ratio (urate/creat) on
fresh urine. A significant increase of the urate/creat ratio
was observed already 4 days after induction (Fig. 3a),
reaching a peak of 11 days after the beginning of the
doxycycline treatment, with an increase of 2.7 ± 1.2 fold
compared to control. Sodium-over-creatinine ratio was
unchanged (Fig. S5a). One month after doxycycline in-
duction, 24-h urine collection was performed in metabolic
cages. Immediate void urines from kiKO and wild-type
mice were clear, whereas a white deposit was apparent
in the urine of kiKO mice left at room temperature
(arrow, Fig. 3b). An increase of urine volume per 24 h
was noted in kiKO mice (Fig. 3b). Urate excretion rate
was markedly increased in kiKO compared to control
mice (7.08 ± 2.27 fold increases, Fig. 3c). No difference
was observed regarding daily food or water intakes, and
the body weight was similar between control and kiKO
mice (not shown). The urinary pH was unchanged be-
tween the two genotypes (6.17 ± 0.46 for control and
6.21 ± 0.30 for kiKO). SUA was significantly different
between male and female mice, but no change was detect-
ed when comparing SUA between control and kiKO mice
(Fig. 3d). Consequently, an increase of the urate fractional
excretion was observed in kiKO mice, for both, male and
female mice (Fig. 3e). The GLUT9 full body knock-out
mouse model presented with a severe nephropathy includ-
ing hydronephrosis, cortical fibrosis, and renal insuffi-
ciency [31]. By contrast, histomorphologic analysis of
kiKO kidneys did not show any change compared to con-
trols (Fig. S5b, c). No fibrosis and no inflammation were
detected, neither by quantification of markers by qPCR
(Fig. S6a), nor by Masson’s trichrome staining (Fig.
S6b). Moreover, kiKO mice plasma creatinine levels were
similar to control mice (17.3 ± 3.2 μM in kiKO versus
17.5 ± 4.7 μM in control), indicating an absence of renal
insufficiency.
Polyuria and water homeostasis in kiKO mice
A 20% increase of the urine volume was observed in the
kiKO mice, with a corresponding trend toward decreased
urine osmolality compared to control mice (Fig. 4a, b).
The urinary concentrating capacity of the kiKO mice was
challenged by a water deprivation test. Mice of the two
genotypes were able to concentrate urine over time (Fig.
4c). Disturbed urine concentration was further explored.
Parts of the cortex and papilla of control and kiKO mice
were isolated and osmolality was measured. Significant
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Fig. 1 GLUT9 is mainly expressed at the basolateral membrane of the
DCT and slightly in the PCT. a Western blot of microdissected tubules
from wild-type mice. GLUT9 is strongly detectable in the DCT. Some
expression is also visible in the PCT after a longer exposure. NCX1 is
used as positive control for the accuracy of the DCT microdissection.
Protein loading can be evaluated by actin quantification. b
Immunostaining of GLUT9 on wild-type kidney section. GLUT9 signal
is restricted to cortical distal convoluted tubules (scale bar: 100 μm). c
Co-immunostaining of GLUT9 and NCX1, and of GLUT9 and AQP2 on
wild-type kidney sections. Both GLUT9 and NCX1 signals are co-
localizing at the basolateral membrane of the DCT. There is no co-
localization of GLUT9 and AQP2 (scale bar: 10 μm)
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and expected increase of the osmolality was observed in the
papilla compared to the cortical part, but no difference in the
corticomedullary osmotic gradient was observed between
control and kiKO mouse kidneys (Fig. 4d). Two important
effectors of water handling by the kidney are aquaporin-2
(AQP2) and the vasopressin receptor type 2 (V2R). By
qPCR, Aqp2 and V2r mRNA expressions in whole kidney
extract were similar in control and kiKO animals (Fig. 5a, b)
under standard conditions and after water deprivation (Fig.
S7). AQP2 protein expression was further analyzed by
Western blot. No significant difference of AQP2 protein
expression was noticed between control and kiKO kidneys
(Fig. 5c).
We previously showed in the full body GLUT9 KO mouse
model that polyuria was accompanied by urine acidification
evoking similar processes found in the hypercalciuric TRPV5
knock-out mice and thought to be mediated by the calcium sens-
ing receptor [15]. We thus tested whether the calcium sensing
receptor (CaSR) could be triggered by high urinary uric acid
levels in the presence of calcium and could mediate polyuria.
We used HEK cells stably expressing CaSR and we exposed
them to increasing concentrations of calcium and urate. As illus-
trated in Fig. S8, no additional activation of CaSR was observed
in presence of urate. Therefore, CaSR seems unlikely to play any
direct role in modulating urine acidification and dilution in these
mice.
Compensatory mechanisms
As presented in Fig. 3c, kiKO mice presented an 8-fold in-
crease of urate excretion rate compared to control mice, but a
normal SUA (Fig. 3d), even though hypouricemia was expect-
ed. We thus looked for possible compensatory mechanisms
that may explain unchanged SUA.
Several organs participate in urate homeostasis, namely the
kidney, the intestinal tract, and the liver. Besides GLUT9,
many transporters are involved in the handling of urate, such
as URAT1, ABCG2, MRP4, OAT1, OAT3, and OAT10 [37].
Moreover, the metabolism of urate in mice is mainly due to
two enzymes: the xanthine oxidase, which mediates the con-
version of xanthine into urate [1], and the uricase, which ca-
tabolize urate into allantoin [41]. Expression analysis of these
different transporters and enzymes was performed by qPCR
on cDNA extracted from the kidney, liver, ileum, and colon of
control and kiKO mice. Results are illustrated in Fig. 6 and
show a down-regulation of the expression of Mrp4 in colon
(Fig. 6c), but otherwise, no other compensatory mechanisms
could be detected.
Blood pressure analysis in kiKO mice
Studies have shown that moderate hyperuricemia may cause
hypertension in rats [27], findings that have been recently
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molecular analysis. a PCR on
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challenged [32].We tookadvantage of the kiKOmousemod-
el to study the impact of increased uric acid excretion on
blood pressure. By telemetry, diastolic and systolic blood
pressures were measured for 1 week. Results in Fig. 7a
showed a slight decrease of both diastolic and systolic blood
pressure. At the same time, an increase of the heart rate was
observed (Fig. 7b).
Discussion
This study identifies GLUT9 as a critical player in renal urate
reabsorption in mice. We showed that loss of expression of
GLUT9 along the renal tubules induces a significant leak of
uric acid in the urine accompanied by an increase in urine
volume. The renal architecture and the filtration capacity were
preserved in these mice.
This model displays some peculiarities compared to pre-
vious GLUT9 KO mice models, especially regarding urine
dilution and SUA levels. GLUT9 constitutive systemic KO
mice developed moderate hyperuricemia, massive hyper-
uricosuria, low urine pH, inability to concentrate urine,
and an early-onset severe nephropathy with intratubular ob-
structive uric acid crystals, tubulointerstitial inflammation,
fibrosis, and progressive renal insufficiency. Liver-specific
inactivation of GLUT9 in adult mice conducted to strong
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analysis. a Time-course of the urate/creatinine ratio from spot urine after
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the difference between control and kiKO mice is still present. Values
are means ± SD (n = 6, *p < 0.05 by Student’s t test). b Twenty-four-
hour urine collection of kiKO mice presents an important white deposit
(arrow) when kept at room temperature. This deposit is made of uric acid
crystals (not shown) and is absent in control urine. The 24-h volume of
kiKO mice urine is higher than the volume of control urine and accord-
ingly, urine is more diluted. c Measurement of 24-h urate excretion rate.
Urate excretion rate for kiKO mice is higher than for controls. Values are
means ± SD (n = 8, *p < 0.05). d SUA analysis. There is no difference
between control (white bars) and kiKO (black bars) mice regarding plas-
ma concentration of urate. Males had higher urate concentration in the
plasma than females. Values are means ± SD (n = 8, *p < 0.05). e
Fractional excretion of urate (FE urate). A significantly higher FE urate
was measured in kiKO mice compared to controls. Values are means ±
SD (n = 8, *p < 0.05)
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elevation of SUA, hyperuricosuria, lower urine pH, and
blunted capability of urine concentration, but no structural
abnormality of the kidney was observed. In this study, renal
tubular inactivation of GLUT9 led to a milder phenotype,
with moderate hyperuricosuria, but with no change in SUA,
urine pH, or renal structure. A moderate increase in urine
volume without alteration of the urine-concentration ability
was also noted. We looked in more details at the correlation
between high uricosuria and urine dilution that was ob-
served in all three GLUT9 KO models [31]. Compared to
the systemic and the liver-specific GLUT9 KO mouse
models, deletion of GLUT9 along the renal tubule did not
affect the overall concentration capacity of the kidney, as
illustrated by a water restriction test. We measured whether
the osmotic gradient along the corticomedullary axis could
be affected and lead to concentrating defect, but it was pre-
served in kiKO mice. We did not observe any difference in
the expression level of the vasopressin receptor V2R or of
the aquaporin 2, even after water restriction. Finally, we
looked for a possible direct role of the calcium sensing
receptor in the observed urate-dependent urine dilution.
Indeed, the calcium sensing receptor—or a similar mecha-
nism—has been proposed to mediate urine dilution in hy-
percalciuria [35] and to play a protective role against
intratubular crystal formation. We tested whether the
CaSR may mediate urate-dependent signaling, but could
not show any influence of increasing urate concentration
on CaSR-dependent signaling. This suggests that other
sensing mechanisms might be involved in this process.
Overall, we could not identify a specific mechanism that
may explain the increased urine dilution in this mouse mod-
el. However, the methods used might not be sensitive
enough to detect small changes as observed in this model
compared to other GLUT9 KO models.
KiKO mice have normal serum uric acid levels despite a
significant loss of uric acid in the urine. This constitutes
one major difference with humans suffering of GLUT9
loss -o f - func t ion muta t ions who disp lay severe
hypouricemia. Several possible explanations could be
brought forward here. First, by contrast to humans, mice
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Fig. 4 More diluted urine in the
hyperuricosuric kiKO mice. a
KiKO mice display an increase
urine volume compared to control
mice. Values are means ± SD (n =
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express uricase and the presence of this enzyme already
reduces SUA to minimal levels that may not allow further
decrease. Studying the kidney-specific role of GLUT9 in
an UOX knock-out background would be a way of
circumventing this limitation [16]. Second, and as ob-
served in the initial description of the model [38], the
PAX8 promoter that drives the cre recombinase expression
leads to some recombination in the liver (Fig. S3). We
previously showed that homozygous—but not heterozy-
gous—deletion of GLUT9 in the mouse liver by using
the albumin-driven cre recombinase led to strong increase
of SUA [31, 33]. Inability of urate to enter hepatocytes
through GLUT9 and be degraded by uricase is thought to
account for this elevation of SUA. In the present model, the
small deletion of GLUT9 in the liver may be enough to
blunt the expected hypouricemia in these mice. Finally,
compensatory mechanisms by other urate transporters in
the kidneys or in other organs may maintain SUA constant
in this mouse model despite the induced renal leak. We
studied the expression levels of the main transporters and
proteins involved in the maintenance of uric acid homeo-
stasis. The only difference between control and kiKO mice
is a decreased expression of the gene coding for MRP4 in
the colon of kiKO mice. Analysis of MRP4 protein expres-
sion levels would be needed before drawing any conclu-
sion, but we can extrapolate that a decreased secretion of
uric acid in the colon would be expected if the decreased
expression of MRP4 would be confirmed at the protein
level. However, if transport of urate was shown in cells
transfected with MRP4 [39], no physiological evidence of
its role in uric acid homeostasis in vivo exists so far, espe-
cially of its role in the colon. Overall, we could not identify
compensation mechanisms in kiKO mice, but further stud-
ies are needed as transcriptional regulation of these trans-
porters has not been explored.
An interesting finding of this report relates to the de-
creased blood pressure observed in kiKO mice. Uric acid
is pointed as a key player in the maintenance of blood
pressure and hyperuricemia is often associated with hyper-
tension. However, causality is debated and Preitner et al.
have recently shown, in an elegant study, that no correla-
tion between SUA and blood pressure is observed when
SUA is increased stepwise [33]. Here, we found that the
renal leak of uric acid lowers blood pressure without chang-
es in SUA. The presence of increased heart rate is however
more suggestive of a slight state of dehydration due to the
increased urine volume. We are not providing data however
to support this working hypothesis and possibility of a di-
rect effect of GLUT9 function in the proximal or distal
tubules remains open. Of note, blood pressure analyses
were carried out only in males and the conclusion may
not apply to females.
As previously related, the phenotype observed in these
mice is different from traits identified in humans suffering
from familial hypouricemia type 2 for several reasons:
presence of a functional hepatic uricase; debated role of
GLUT9 in the human liver; and debated localization and
sorting of GLUT9 isoforms in the different segments of the
kidneys. Here, we confirmed unambiguously that in the
mouse, GLUT9 is mainly located in the distal convoluted
tubule [17], with lower expression in the proximal convo-
luted tubule, while this carrier is located exclusively in the
proximal tubules in humans [4]. The sorting of mouse and
human GLUT9 isoforms in cells seems also to differ.
Mouse GLUT9 isoforms are expressed at the basolateral
side of MDCK transfected cells [17], a pattern compatible
with our own data (Fig. 1c). For human isoforms, some
controversies exist. The long isoform is consistently
expressed at the basolateral side of MDCK transfected
cells, whereas the short isoform is described either only
at the apical side [4] or at both apical and basolateral sides
of MDCK transfected cells [18]. Altogether, mice have a
unique expression pattern of GLUT9 in the distal convo-
luted tubule that is of unknown function. Expression at a
lower level in the proximal tubule is compatible with a
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more traditional role in transcellular reabsorption of uric
acid in this part of the tubule.
Overall, this work identifies GLUT9 as a critical partner in
renal uric acid handling and more precisely in urate
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reabsorption. It points to a role of GLUT9 in the mouse distal
convoluted tubule that remains unknown. Loss-of-function
mutations in humans lead to severe hypouricemia, at the level
of uricase-expressing species [34]. Mice with renal specific
deletion of GLUT9 do not display hypouricemia even in pres-
ence of urate leak, but have higher urine volume and lower
blood pressure. Extrapolation of this data to humans should be
made only with caution as several differences are prominent in
the way uric acid is handled in these two species.
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